Clinical trials: Prostatic Disease
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
This is a phase 2 study to evaluate the safety and effectiveness of light-activated talaporfin sodium in patients with LUTS due to benign prostatic hyperplasia (BPH).
- Trial name
- NCT00918034
- Testing
- talaporfin sodium, Transurethral illumination with light emitting diodes, Placement
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 21 people
- Sponsor
- Light Sciences Oncology
Prostate Cancer
Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose…
- Trial name
- NCT03120832
- Testing
- PAN-301-1
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Nocturia, Prostatic Hyperplasia
A Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
- Trial name
- NCT00793819
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 215 people
- Sponsor
- Watson Pharmaceuticals
Prostate Cancer
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
The purpose of this trial was to see how well a new trial drug (degarelix) worked on lower urinary tract symptoms (also known as LUTS) in prostate cancer patients as compared to how a standard drug hormonal treatment worked on…
- Trial name
- NCT00831233
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 33 sites in Germany, Spain and 1 more
- Volunteers
- 42 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer, Endometriosis
A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
This is a nonrandomized, open-label, fixed-sequence, 2-arm study designed to assess the effect of multiple doses of fluconazole or atorvastatin on the single-dose pharmacokinetics of TAK-385 in healthy adult subjects.
- Trial name
- NCT02093390
- Testing
- TAK-385, Fluconazole, Atorvastatin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Castration-Resistant Prostate Cancer
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
The purpose of this study is to determine whether daily treatment with apalutamide affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC)
- Trial name
- NCT02578797
- Testing
- Apalutamide
- Where
- 5 sites in United States, Canada and 3 more
- Volunteers
- 45 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
LE-DT is a novel, proprietary delivery system of docetaxel developed by NeoPharm, Inc. Docetaxel (currently marketed as Taxotere) is an anti-microtubular network agent and is one of the most active agents in the treatment of…
- Trial name
- NCT01188408
- Testing
- Liposome Entrapped Docetaxel (LE-DT)
- Where
- 2 sites in United States
- Sponsor
- INSYS Therapeutics Inc
Prostate Cancer
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.
- Trial name
- NCT00060476
- Testing
- rofecoxib
- Volunteers
- 15,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added onto hormone therapy can improve PSA progression times for patients with Metastatic Prostate Cancer.
- Trial name
- NCT02107391
- Testing
- Dendritic Cells DCVAC/PCa, Leuprolide acetate, Goserelin Acetate
- Where
- 9 sites in Czechia
- Volunteers
- 63 people
- Sponsor
- SOTIO a.s.
Benign Prostatic Hypertrophy
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is characterized by an enlargement of the prostate occurring in human male over the age of 50 which increases in prevalence with age, and…
- Trial name
- NCT00449150
- Testing
- Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg
- Where
- 68 sites in United States, Bulgaria and 2 more
- Volunteers
- 667 people
- Sponsor
- AEterna Zentaris
Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction
Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.
- Conditions
- Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction, Prostate Cancer, Radical Prostatectomy
- Trial name
- NCT05558007
- Testing
- Tadalafil 5mg, BZ371A
- Where
- Brazil
- Volunteers
- 72 people
- Sponsor
- Biozeus Biopharmaceutical S.A.
Blood Loss, Surgical, Prostate Cancer
Safety Study of Hemospan® in Prostatectomy Patients
This is a progressive dose escalation study designed to evaluate the safety of Hemospan compared to a standard crystalloid solution (Ringer's lactate) in elective surgery patients undergoing total prostatectomy procedures with…
- Conditions
- Blood Loss, Surgical, Prostate Cancer, Surgery
- Trial name
- NCT00425334
- Testing
- Hemospan (MP4OX), Ringer's lactate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sangart
Advanced/Metastatic Solid Tumors
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in…
- Trial name
- NCT04182516
- Testing
- NMS-03305293
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 52 people
- Sponsor
- Nerviano Medical Sciences
Prostate Cancer, Neoplasm Metastasis
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Multicenter study in which patients with metastatic hormone refractory prostate cancer (HRPC), who have not had previous chemotherapy or immunotherapy treatments, received MDX-010 every 3 weeks for 4 doses (12 weeks total…
- Trial name
- NCT00323882
- Testing
- MDX-010
- Where
- 14 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer, Prostate Cancer Recurrent
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
This study evaluates the diagnostic performance and safety of [18F]PSMA-1007 PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.
- Trial name
- NCT04742361
- Testing
- [18F]PSMA-1007
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 136 people
- Sponsor
- ABX advanced biochemical compounds GmbH
Benign Prostatic Hyperplasia
Evaluating the Safety and Efficacy of the "HIFU" High-intensity Focused Ultrasound Treatment of Benign Prostatic Hyperplasia;
Prostate adenoma, also known as benign prostatic hypertrophy or hyperplasia (BPH), involves an increase in the size of the prostate, forming a benign tumor.
- Trial name
- BPH EFFICACY (NCT06601179)
- Testing
- HIFU
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- EDAP TMS S.A.
Tumors, Prostate Cancer
A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel
This is a single-center, open-label (sequential-group dose-escalation dose-finding) phase I study of satraplatin and docetaxel in patients who have received prior chemotherapy regimens.
- Trial name
- NCT00313456
- Testing
- Satraplatin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Agennix
Prostate Cancer
Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy
The objective of the study is to compare the evolution over 6 months of Health-Related Quality of Life (HRQOL) among different age groups in subjects with prostate cancer treated with GnRH agonist therapy.
- Trial name
- PRISME (NCT03516110)
- Testing
- Data collection
- Where
- France
- Volunteers
- 831 people
- Sponsor
- Ipsen
HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
The goal of this Phase 1/2a interventional study is to evaluate the safety and tolerability of CRG-150 in relapsed/refractory HR+HER2- breast cancer, Triple Negative Breast Cancer (TNBC) and prostate cancer.
- Conditions
- HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer
- Trial name
- NCT07730125
- Testing
- CRG-150
- Volunteers
- 67 people
- Sponsor
- CoRegen, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.